15.64% Average Return, Two Ideas Up 25%+, One Up 50%+ - Introducing The Clinical Edge Index
Complete transparency with skin in the game.
To read our full disclaimer, click here.
The Clinical Edge is now 3 months old and has covered 5 different companies.
As coverage expands, I’m launching The Clinical Edge Index to track performance from publication date.
Pure transparency with skin in the game.
Equal weights. No rebalancing. No trading.
Just buy-and-hold measurement from day one.
This isn’t a model portfolio or investment advice.
It’s a transparency tool to see if systematically identifying asymmetric healthcare bets can beat index returns over time.
The index is new, so judge it over the long run, not quarter-to-quarter.
Short-term performance shouldn’t encourage short-term thinking.
Current Performance
The index has 5 positions across the USA and Canada.
You can see the current performance of the index here:
The full Index can be viewed at the end of this post.
Stock 1
Stock 2
Stock 3
Stock 4
Stock 5
What Paid Subscribers Get
Subscribers get complete access to the The Clinical Edge Index below as well as 2-4 new company analyses monthly, like the ones showcased in this post.
Annual plans are also 34% cheaper for those that like some great value.
If that sounds like something you’re interested in, you can view the full index with this link or at the end of the post:
No worries if not.
Thanks for reading and have a great rest of your day,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.